The ALS Association is partnering with MyTomorrows, a global health technology company, to make it easier for people…
Articles by Andrea Lobo, PhD
Health Canada is now reviewing Qalsody (tofersen) as a potential treatment for people with amyotrophic lateral sclerosis (ALS) who carry mutations in…
Coave Therapeutics has received a grant from the ALS Association to support the development of its gene therapy…
Daily treatment with monepantel — a drug widely used in veterinary medicine — was shown to reduce the rate…
Treatment with NeuroSense Therapeutics’ PrimeC was found to extend patients’ time without complications or death, and to lead to…
OrphAI Therapeutics’ experimental therapy AIT-101 has been awarded orphan drug status in the European Union for amyotrophic lateral…
An advisory committee of the European Medicines Agency (EMA) has recommended that Biogen’s Qalsody (tofersen) be approved in the…
ProJenX has been given the green light to expand its ongoing Phase 1 clinical trial of prosetin for amyotrophic…
TPN-101, an investigational oral molecule developed by Transposon Therapeutics, reduced multiple biomarkers of neuroinflammation and neurodegeneration, and slowed respiratory…
Myrobalan Therapeutics will use a $400,000 grant from the ALS Association — along with $24 million in new…